BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 21126213)

  • 1. Targeting enteral endocrinal L-cells with dietary carbohydrates, by increasing the availability of miglitol in the intestinal lumen, leads to multi-fold enhancement of plasma glucagon-like peptide-1 levels in non-diabetic canines.
    Deshpande MC; Venkateswarlu V; Mantri AH; Gadewar ST
    Drug Dev Ind Pharm; 2011 May; 37(5):506-17. PubMed ID: 21126213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels.
    Deshpande MC; Venkateswarlu V; Babu RK; Trivedi RK
    Int J Pharm; 2009 Oct; 380(1-2):16-24. PubMed ID: 19563873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
    Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
    Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The intestine responds to heart failure by enhanced mitochondrial fusion through glucagon-like peptide-1 signalling.
    Naruse G; Kanamori H; Yoshida A; Minatoguchi S; Kawaguchi T; Iwasa M; Yamada Y; Mikami A; Kawasaki M; Nishigaki K; Minatoguchi S
    Cardiovasc Res; 2019 Nov; 115(13):1873-1885. PubMed ID: 30629149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
    Arakawa M; Ebato C; Mita T; Fujitani Y; Shimizu T; Watada H; Kawamori R; Hirose T
    Metabolism; 2008 Sep; 57(9):1299-306. PubMed ID: 18702958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct action of the α-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion.
    Lee EY; Kaneko S; Jutabha P; Zhang X; Seino S; Jomori T; Anzai N; Miki T
    J Endocrinol; 2015 Mar; 224(3):205-14. PubMed ID: 25486965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of efficacy and safety of taking miglitol dissolved in water during a meal and taking a miglitol tablet just before a meal in patients with type 2 diabetes.
    Shibata E; Aoki K; Tajima K; Taguri M; Terauchi Y
    Expert Opin Pharmacother; 2016; 17(7):889-94. PubMed ID: 26918556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.
    Hiki M; Shimada K; Kiyanagi T; Fukao K; Hirose K; Ohsaka H; Fukushima Y; Kume A; Matsumori R; Sumiyoshi K; Miyazaki T; Ohmura H; Kurata T; Miida T; Daida H
    Circ J; 2010 Jul; 74(7):1471-8. PubMed ID: 20519875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50.
    Kimura T; Suzuki J; Ichikawa M; Imagawa M; Sato S; Fujii M; Zenimaru Y; Inaba S; Takahashi S; Konoshita T; Miyamori I
    Diabetes Technol Ther; 2012 Jul; 14(7):545-51. PubMed ID: 22519736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice.
    Hamada Y; Nagasaki H; Fuchigami M; Furuta S; Seino Y; Nakamura J; Oiso Y
    Metabolism; 2013 May; 62(5):734-42. PubMed ID: 23194643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the efficacy of α-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study.
    Tsujino D; Nishimura R; Taki K; Morimoto A; Tajima N; Utsunomiya K
    Diabetes Technol Ther; 2011 Mar; 13(3):303-8. PubMed ID: 21291335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro study of the effect of miglitol on carbohydrate digestion and intestinal metabolism in normal and non-insulin-dependent diabetic rats.
    Tormo MA; Ropero MF; Nieto M; Martinez IM; Campillo JE
    Can J Physiol Pharmacol; 1996 Nov; 74(11):1196-203. PubMed ID: 9028577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Delayed absorption of carbohydrates in the therapy of Type II diabetes: comparison between dietary (Muesli) and pharmacological (Alpha-glucosidase inhibition) modification].
    Willms B; Lübke D; Ahrens K; Arends J
    Schweiz Med Wochenschr; 1991 Sep; 121(38):1379-82. PubMed ID: 1656521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
    Seifarth C; Bergmann J; Holst JJ; Ritzel R; Schmiegel W; Nauck MA
    Diabet Med; 1998 Jun; 15(6):485-91. PubMed ID: 9632123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients.
    Narita T; Katsuura Y; Sato T; Hosoba M; Fujita H; Morii T; Yamada Y
    Diabet Med; 2009 Feb; 26(2):187-8. PubMed ID: 19236625
    [No Abstract]   [Full Text] [Related]  

  • 16. Resistant maltodextrin promotes fasting glucagon-like peptide-1 secretion and production together with glucose tolerance in rats.
    Hira T; Ikee A; Kishimoto Y; Kanahori S; Hara H
    Br J Nutr; 2015 Jul; 114(1):34-42. PubMed ID: 25671387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
    Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
    Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease.
    Emoto T; Sawada T; Hashimoto M; Kageyama H; Terashita D; Mizoguchi T; Mizuguchi T; Motodi Y; Iwasaki M; Taira K; Okamoto H; Matsuo Y; Kim SK; Takarada A; Yokoyama M
    Am J Cardiol; 2012 Jan; 109(1):42-6. PubMed ID: 21944671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effect of black tea and its combination with acarbose on small intestinal α-glucosidase activity.
    Satoh T; Igarashi M; Yamada S; Takahashi N; Watanabe K
    J Ethnopharmacol; 2015 Feb; 161():147-55. PubMed ID: 25523370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.